12:00 AM
Jan 21, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Radium-223 regulatory update

Algeta said the U.S. Nuclear Regulatory Commission determined that its radium-223 can be used for medical use. Last December, Algeta's partner Bayer submitted an NDA to FDA...

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >